Brief: Aerovate Therapeutics Announces Simultaneous Completion Of Enrollment In Phase 2B Portion And Enrollment Of First Patient Into Phase 3

Jade Biosciences

20/11/2023 21:50

Nov 20 (Reuters) - Aerovate Therapeutics Inc  AVTE.O :
    * AEROVATE THERAPEUTICS ANNOUNCES SIMULTANEOUS COMPLETION OF
ENROLLMENT IN PHASE 2B PORTION AND ENROLLMENT OF FIRST PATIENT
INTO PHASE 3 IN THE IMPAHCT TRIAL EVALUATING AV-101 FOR THE
TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    * AEROVATE THERAPEUTICS INC - TOPLINE PHASE 2B DATA EXPECTED
IN
JUNE 2024
    * AEROVATE THERAPEUTICS INC - IN ADDITION, FIRST PATIENT HAS
BEEN
ENROLLED IN PHASE 3 PORTION OF IMPAHCT

Source text for Eikon:  ID:nGNX1F794l 
Further company coverage:  AVTE.O 

 ((Reuters.Briefs@thomsonreuters.com;))